9 months ago
RIGL
AnalystsKalpit PatelKalpit Patel's Stock Forecasts
AnalystsKalpit Patel
Sectors:
Analyst Ranking
Bottom 19%
#4201 out of 5156 analysts
Average Return
-0.24%
Win Rate
47%25 out of 53
Risk vs Reward
Poor
Good
Kalpit Patel's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Longboard Pharmaceuticals IncLBPH | +209.09% | $19.09 | $58.99 | 2024-06-10 - 2024-10-14 | Strong Buy |
Journey Medical CorpDERM | +186.29% | $1.24 | $3.55 | 2023-05-22 - 2024-05-22 | Strong Buy |
Journey Medical CorpDERM | +174.40% | $2.07 | $5.68 | 2023-07-11 - 2024-07-11 | Strong Buy |
Journey Medical CorpDERM | +160.62% | $1.41 | $3.68 | 2023-03-29 - 2024-03-28 | Strong Buy |
Longboard Pharmaceuticals IncLBPH | +136.17% | $8.35 | $19.72 | 2023-04-26 - 2024-04-26 | Strong Buy |
Kalpit Patel Analyst Color
Get additional color on Kalpit Patel's coverage of popular stocks
a year ago
LBPH
Kalpit Patel's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Pds Biotechnology CorpPDSB | 6 | Strong Buy | $3.00 | +246.42% | Maintains | 23 days ago |
Scholar Rock Holding CorpSRRK | 1 | Buy | $42.00 | -4.57% | Initiates Coverage On | a month ago |
Soleno Therapeutics IncSLNO | 1 | Buy | $75.00 | +52.28% | Initiates Coverage On | a month ago |
Revolution Medicines IncRVMD | 1 | Buy | $75.00 | -2.27% | Initiates Coverage On | a month ago |
Celcuity IncCELC | 1 | Buy | $110.00 | +11.06% | Initiates Coverage On | a month ago |
Journey Medical CorpDERM | 6 | Strong Buy | $12.00 | +54.64% | Maintains | 5 months ago |
Kymera Therapeutics IncKYMR | 5 | Strong Buy | $60.00 | -26.89% | Upgrades | 6 months ago |
Bicycle Therapeutics PLCBCYC | 7 | Hold | $14.00 | +101.44% | Maintains | 8 months ago |
Arrivent Biopharma IncAVBP | 1 | Strong Buy | $37.00 | +66.37% | Initiates Coverage On | 9 months ago |
Rigel Pharmaceuticals IncRIGL | 6 | Hold | $24.00 | -42.78% | Maintains | 9 months ago |
Geron CorpGERN | 4 | Strong Buy | $3.50 | +150.00% | Maintains | 10 months ago |
Verastem IncVSTM | 4 | Strong Buy | $9.00 | +13.07% | Maintains | a year ago |
Foghorn Therapeutics IncFHTX | 1 | Strong Buy | $10.00 | +115.52% | Initiates Coverage On | a year ago |
Longboard Pharmaceuticals IncLBPH | 4 | Hold | $60.00 | N/A | Downgrades | a year ago |
Corbus Pharmaceuticals Holdings IncCRBP | 2 | Strong Buy | $40.00 | N/A | Maintains | a year ago |
Ovid Therapeutics IncOVID | 2 | Strong Buy | $3.00 | N/A | Maintains | 2 years ago |
Viridian Therapeutics IncVRDN | 3 | Hold | $20.00 | N/A | Downgrades | 2 years ago |
X4 Pharmaceuticals IncXFOR | 1 | Hold | $30.00 | N/A | Downgrades | 2 years ago |
Mirati Therapeutics IncMRTX | 5 | Hold | $60.00 | N/A | Downgrades | 2 years ago |
Syndax Pharmaceuticals IncSNDX | 2 | Strong Buy | $36.00 | N/A | Maintains | 2 years ago |
Infinity Pharmaceuticals IncINFI | 1 | Hold | $1.50 | N/A | Downgrades | 3 years ago |
In8bio IncINAB | 3 | Hold | $90.00 | N/A | Downgrades | 3 years ago |
Allogene Therapeutics IncALLO | 2 | Strong Buy | $18.00 | N/A | Maintains | 3 years ago |
Entera Bio LtdENTX | 1 | Strong Buy | $5.00 | N/A | Maintains | 3 years ago |
Vincerx Pharma IncVINC | 2 | Strong Buy | $120.00 | N/A | Maintains | 4 years ago |
Mink Therapeutics IncINKT | 1 | Strong Buy | $10.00 | N/A | Maintains | 4 years ago |
Dianthus Therapeutics IncDNTH | 2 | Strong Buy | $6.00 | N/A | Maintains | 4 years ago |
Forte Biosciences IncFBRX | 2 | Hold | $75.00 | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.